Promoter Hypermethylation Analysis of the Tumor Suppressor Genes RASSF1A and RASSF2A in Iranian Endometrial Carcinoma Patients
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 4
Abstract
Introduction The endometrial cancer (EC) is the seventh most common malignancies worldwide among females with good prognosis in early stages of the disease. The CpG Island in the promoter region of tumor-suppressor genes are frequently methylated in various types of human cancers. In the present study, we investigated the methylation pattern in promoter region of <i>RASSF1A</i> and RASSF2A genes in Endometrial cancer patients in Iranian women to identify correlations among promoter hypermethylation, disease risk and clinicopathological parameters. Methods 28 patients and 22 healthy controls were studied. Isolation of genomic DNA from FFPE and peripheral blood was performed and Methylation-Specific PCR (MSP) was applied for analysis of the promoter CpG methylation status of <i>RASSF1A</i> and RASSF2A genes in the studied population. Results A significant difference was found among the study groups and the presence of promoter CpG hypermethylation status in the <i>RASSF1A</i> (P = 0.0321) and <i>RASSF2A </i>(P = 0.0003) genes. <i>RASSF1A</i>, and <i>RASSF2A</i> gene promoter methylations were present in 53.57% and 42.85% of EC samples when compared to those in the controls with 31.81% and 9.09% respectively. Furthermore, methylation status between tissue and blood samples of <i>RASSF1A</i>, and RASSF2A genes was not significant (P = 0.49 and 0.09 respectively). Our results indicated a corollation between ages, menosososal state and tumor grade with <i>RASSF1A</i>, and <i>RASSF2A</i> promoter methylation. Conclusions In our study, Hypermethylation of both <i>RASSF1A</i> and <i>RASSF2A</i> genes are important events in carcinogenesis of endometrial cancer. Epigenetic alternations may have diagnostic value for early diagnosis and better clicinal management of susceptibility to endometrial malignancies.
Authors and Affiliations
Neda Jabbara, Golnaz Asaadi Tehrani, Fatemeh Lalooha, Seyed Amir Farzam, Khadijeh Elmizadeh
Keywords
Related Articles
- EP ID EP237357
- DOI 10.5812/ijcm.8629
- Views 82
- Downloads 0
Prognostic Factors and Survival of Glioblastoma Multiform (GBM) in Iranian Patients
Background Glioblastoma Multiform has been a common and fatal brain tumor. In this regard, there was ambiguity around patient survival rates in Iran que to data insufficiency. In...
Positive Peritoneal Cytology as a Predictor of Prognosis in Early Stage of Endometrioid Adenocarcinoma
Background Peritoneal cytology has been reported to be an independent risk factor for poor survival, but it is not included in the current international federation of gynecology a...
Immunohistochemical Study of HER2/neu Expression in Colorectal Cancer and its Relation to other Clinicopathological Criteria and Prognostic Factors
Background: Human epidermal growth factor receptor 2 (HER2) overexpression and amplification have been studied as a therapeutic and prognostic target in a number of tumors although conflicting data exist about the incide...
Supraclavicular Metastasis from Infraclavicular Organs: Retrospective Analysis of 18 Patients
Background Supraclavicular fossa masses have usually been malignant lesions. When fine needle aspiration biopsy results have not been satisfactory excisional biopsy of supraclavic...
Effect of Simultaneous Treatment with Royal Jelly and Doxorubicin on the Survival of the Prostate Cancer Cell Line (PC3): An In Vitro Study
Background: Doxorubicin (DOX) therapy is the first step in the treatment of several malignancies such as prostate cancer. Drug resistance is the main drawback of this agent. Royal jelly (RJ), used to prevent or cure many...